NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Evaluation of Attentional Performance in Parkinson Disease

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Neurological Disorders and Stroke (NINDS)

Recruitment Detail

Type: Recruitment has not started
Gender: Male & Female
Min Age: 35
Max Age: 80

Referral Letter Required


Population Exclusion(s)

Pregnant Women and Fetuses;
Non-English Speaking

Special Instructions

Currently Not Provided


Functional Connectivity;
Visual Attention;
Dopamine Depletion;
Landmark Test

Recruitment Keyword(s)



Parkinson's Disease

Investigational Drug(s)


Investigational Device(s)




Supporting Site

National Institute of Neurological Disorders and Stroke


Parkinson Disease (PD) is a nervous system disorder that affects movement. Dopamine is an important neurotransmitter in the brain. As PD progresses, there is less and less dopamine in the brain. Researchers think there may be a relationship between differences in attention and dopamine in people with PD.


To learn if people with PD that is worse on one side also have differences in how much attention they pay to the two sides of space on their left and right.


English-speaking, right-handed people age 35-80 with PD.


Participants will be screened with medical and neurological history and exam, and medicine review.

Participants will have 1 study visit. It will last 7-8 hours. They will stop taking their Parkinson medicine 12 hours before the visit.

Participants will complete questionnaires.

Participants will do tasks on a computer screen. They will judge the middle of lines, react to stimuli, and search and identify items that appear on the screen.

Participants may have functional and structural magnetic resonance imaging (MRI). MRI uses a strong magnetic field and radio waves to take pictures of the brain. During the MRI, participants will lie on a table that slides in and out of the MRI scanner. While inside the scanner, they will look at a cross on a screen, relax, and think about nothing.

Participants will undergo prism adaptation. They will sit in front of a board while their chin rests on a support. They will point to 1 of 2 dots on the board while they wear prism glasses that shift their vision to the left or right.

--Back to Top--



1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Male or female aged 35 - 80 (inclusive)

4. Fluent in English

5. Right-handed per the Edinburgh Handedness scale

6. Able to provide consent

7. Diagnosis of idiopathic Parkinson s disease according to UK Brain Bank criteria

8. On dopaminergic therapy to treat Parkinsonian symptoms

9. MOCA Score greater than or equal to 24 determined by a NIH neurologist

10. Hoehn and Yahr Score less than or equal to 3 determined by a NIH neurologist

11. Asymmetric motor symptoms


1. Any current major neurological or psychiatric disorder other than Parkinson s disease, such as, (but not limited to) stroke, dementia, Alzheimer disease, Schizophrenia or Major Depression Disorder

2. Inability to provide consent

3. Members of the Behavioral Neurology Unit, NINDS

4. Left-handed per the Edinburgh Handedness scale

5. Primarily axial motor symptoms or symmetrical limb involvement

6. Pregnancy

7. Exclusion criteria for MRI

-Presence of metal which would make having an MRI scan unsafe, such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, artificial heart valves, cochlear implants or shrapnel fragments, or if subject was a welder or metal worker, since small metal fragments may be present in the eye.


-Inability to lie supine comfortably for 1 hour



Because the goals of the study can be accomplished without involving vulnerable population, we will not include individuals without consent capacity.

Since the goal is to characterize visuospatial attention deficits in idiopathic PD which is a disease of late adulthood, we will not include children.

The effects of MRI on fetal development and the health of pregnant women is unknown.

Therefore, women who are pregnant and breast-feeding will be excluded and women who can become pregnant will be excluded following a positive pregnancy test, if the optional MRI is under consideration.

The study requires fluency in English in order to completely understand tasks instructions, thus non-English speakers/readers will be excluded.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Eric M. Wassermann, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)

Amelia G. Stapleton
National Institute of Neurological Disorders and Stroke (NINDS)
BG 10 RM 7D48
(301) 435-6624

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: 1-866-411-1010

Clinical Trials Number:


--Back to Top--